External broker reports(aggregated public sources), Ord Minnett

Ord Minnett

External broker reports(aggregated public sources)

Ord Minnett is a leading Australian wealth management group, incorporating full-service stockbroking, financial planning and funds management. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>With the timing of the Philips reseller agreement weighing on investors, we believe 4DX’s improving US commercialisation trajectory is being underappreciated.</li><li>The company’s CT LVAS product has been granted reimbursement at US$650 per scan – well ahead of expectations on both timing and quantum (2.2x XV LVAS reimbursement).</li><li>This represents a step- change in 4DX’s unit economics and is likely to see CT LVAS repositioned as its core/front-line screening product (underpinned by higher reimbursement, broader CT utilisation tailwinds). </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

With the timing of the Philips reseller agreement weighing on investors, we believe 4DX’s improving US commercialisation trajectory is being underappreciated.The company’s CT LVAS product has been granted reimbursement at US$650 per scan – well ahead of expectations on both timing and quantum (2.2x XV LVAS reimbursement).This represents a step- change in 4DX’s unit economics and is likely to see CT LVAS repositioned as its core/front-line screening product (underpinned by higher reimbursement, broader CT utilisation tailwinds). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<ul><li>4DX’s 1H24 result was largely in-line with OMLe across key metrics (revenue, cash flows, balance sheet), noting the majority were pre-reported at the 2Q24 release (Jan-24).</li><li>The company’s underlying cost base was better than expected (opex -5% vs pcp, -14% vs OMLe), highlighting strong cost control despite significant commercialisation progress.</li><li>While recent Imbio wins are incrementally positive (Blackford deal, VA research study), the bigger 2H24 catalysts include a Philips reseller agreement, VA progress (2nd ATO, proof of concept trial) and expansion of the Australian installed base. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

4DX’s 1H24 result was largely in-line with OMLe across key metrics (revenue, cash flows, balance sheet), noting the majority were pre-reported at the 2Q24 release (Jan-24).The company’s underlying cost base was better than expected (opex -5% vs pcp, -14% vs OMLe), highlighting strong cost control despite significant commercialisation progress.While recent Imbio wins are incrementally positive (Blackford deal, VA research study), the bigger 2H24 catalysts include a Philips reseller agreement, VA progress (2nd ATO, proof of concept trial) and expansion of the Australian installed base. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

4Dmedical Limited - Significant Progress in 1H24

<ul><li>We initiate coverage of 4DMedical (4DX) with a $1.20 price target and a Speculative Buy recommendation.</li><li>4DX is a global medical technology company focused on the commercialisation of its flagship respiratory imaging platform, XV Technology.</li><li>We believe the company is strongly positioned to disrupt the US$31b global respiratory diagnostics market, with its software products offering a step-change in diagnostic capability vs incumbent modalities (e.g. chest X-rays, CTs). </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We initiate coverage of 4DMedical (4DX) with a $1.20 price target and a Speculative Buy recommendation.4DX is a global medical technology company focused on the commercialisation of its flagship respiratory imaging platform, XV Technology.We believe the company is strongly positioned to disrupt the US$31b global respiratory diagnostics market, with its software products offering a step-change in diagnostic capability vs incumbent modalities (e.g. chest X-rays, CTs). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Australia

4DMedical Ltd develops software. The Company designs application for medical field. 4DMedical serves customers in the United States and Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

4DMedical (4DX AU)

4DMedical - Pricing Step-Change

With the timing of the Philips reseller agreement weighing on investors, we believe 4DX’s improving US commercialisation trajectory is being...

Ord Minnett

4Dmedical Limited - Significant Progress in 1H24

4DX’s 1H24 result was largely in-line with OMLe across key metrics (revenue, cash flows, balance sheet), noting the majority were pre-reported at...

Ord Minnett

4DMedical Limited - Owning the Lung

4DX is a global medical technology company focused on the commercialisation of its flagship respiratory imaging platform, XV Technology.

Ord Minnett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)